Key Highlights

  • Arbutus Biopharma (NASDAQ:ABUS) screens with trailing Revenue growth of 1,078.78%, a 99.98% gross Margin and an 84.23% net margin. The cause is one-time license revenue from its share of a Moderna settlement, not recurring sales.
  • The company booked USD 179.1 million of revenue in the first quarter of 2026, up from USD 1.8 million a year earlier. Second quarter revenue fell to USD 1.0 million with a net loss of USD 5.1 million.
  • A modified Dutch auction tender offer for USD 230 million expired September 29, 2026 at 5:00 p.m. New York City time. The purchase price was USD 5.00 per share, and 46,000,000 shares were bought.
  • The stock traded near USD 4.15 on October 8, 2026, down 3.26%, about 17% below the tender price by our own arithmetic. No new company announcement for that day was found.

Why the Growth Figure Is a Base Effect

Arbutus Biopharma (NASDAQ:ABUS) develops hepatitis B treatments and licenses lipid nanoparticle patents to Genevant, a company in which it owns about 16%. On March 3, 2026 Arbutus and Genevant settled Patent litigation with Moderna. Moderna agreed to pay USD 950 million upfront, paid in July 2026, and Arbutus booked its expected share of about USD 178.7 million as license revenue in the first quarter ended March 31, 2026. That compares with USD 1.8 million in the first quarter of 2025. Because the screen sums trailing revenue, the 1,078.78% growth, 81.13% Operating Margin and 89.58% Return on Equity all reflect that single event and will not repeat.

What Happened to the Cash

Arbutus received about USD 178.4 million on July 8, 2026, after quarter end, so cash was USD 92.6 million at June 30, 2026. The company then launched a tender offer on August 24, 2026 for up to USD 230 million at USD 5.00 to USD 5.75 per share. The final result, announced October 1, 2026, was a USD 5.00 purchase price and 46,000,000 shares, about 23% of those outstanding. Holders tendered 65,709,919 shares, so the offer was oversubscribed. Roivant Sciences, with about 19.5%, tendered proportionately and expects to keep that stake. Settlement was expected on or about October 5, 2026, leaving about 153.3 million shares.

Risks and What Remains

Revenue now depends on small license and Royalty streams, so quarterly losses should be expected until a product or another settlement arrives. A further USD 1.3 billion from Moderna is contingent on an appellate ruling with no date given. In July 2026 Arbutus and Genevant filed three international lawsuits against Pfizer and BioNTech in 21 countries. Imdusiran received FDA Fast Track Designation in April 2026, and a Phase 2b trial protocol is still being finalized. The company also expects a material Genevant Dividend in the third quarter of 2026. The screen market cap of USD 822 million may predate the buyback, and at about 153.3 million shares the same price implies roughly USD 636 million, our own arithmetic.

Where Things Stand

Arbutus Biopharma (NASDAQ:ABUS) shows 1,078% revenue growth because the Moderna settlement revenue of about USD 178.7 million landed in the first quarter of 2026 against a tiny base, while recent quarters earn little. The USD 230 million tender closed at USD 5.00, and the stock trades below that price. Upcoming items include the third quarter report, the Genevant dividend, the appellate ruling and the imdusiran Phase 2b protocol, none with confirmed dates. Revenue quality here is low and the pipeline is the long term story.